。SRNE is up nearly 90% today on 40X average trading volume, this is a show of tremendous interest by investors on this stock.
。SRNE rejected two $3 to $5 per share range buyout offers. SRNE board think this price range is significantly undervalued the company. SRNE believes its immuno-oncology products have short- and long-term value and has said it is in advanced discussions with other biopharmas for collaboration and licensing of its products. Higher take over price offers may be coming in.
。SRNE owns a 25% equity stake in Celularity, a biopharma start-up created with help from Celgene and United Therapeutics, that's valued at approximately $1 billion. Considering SRNE is only about$220 million, its price can easily double.
。Analysts consensus 1 year price target is $24.50, a near 800% increase from today's price.
。Estimated next year EPS is +60% and average +37% for the next 5 year.
T。echnically, SRNE broke above 200 day moving average at $2.69 and filled gap to $3.2 from end of June 2019. Next resistances are 4 and 6.5. Support is 2.69.
Sorrento Therapeutics，Inc.（SRNE 3.05）是临床阶段的生物技术公司，主要从事发现和开发专注于肿瘤学和全球慢性癌痛治疗的疗法。
。SRNE今天以40倍平均交易量上升了近90％，这表明投资者对该股票表现出极大的兴趣。
。SRNE拒绝了两家公司每股3至5美元的股票收购要求。 SRNE董事会认为该价格范围对公司价值极度低估了。 SRNE认为其免疫肿瘤学产品具有短期和长期价值，并表示正在与其他生物制药公司就其产品的协作和许可进行深入商讨。可能会有更高的收购价格提议。
。SRNE拥有Celularity 25％的股份，Celularity是一家在Celgene和United Therapeutics的帮助下创立的生物制药初创公司，价值约为10亿美元。 而SRNE今天的市值只是2.2亿美元，这可以导致SRNE的股价很容易的翻番。
。分析师综合1年目标价为24.50美元，较当前价格高近近800％。
。估计明年每股收益为+ 60％，未来五年平均为+ 37％。
。技术上，SRNE突破了200日移动平均线2.69美元，并填补了2019年6月底造成的缺口价3.2美元。下一个阻力位是4和6.5美元。支撑位是2.69美元。
No comments:
Post a Comment